Relmada Therapeutics, INC Form 4 insider transactions

RELMADA THERAPEUTICS CEO Sergio Traversa acquired 27,500 shares of common stock and was granted 1.2 million Stock Appreciation Rights.

RELMADA Therapeutics' Chief Financial Officer, Maged Shenouda, acquired 11,665 common shares and was granted 828,000 stock appreciation rights.

RELMADA Therapeutics officer Chuck Ence was granted 828,000 stock appreciation rights with a $4.06 exercise price, vesting quarterly from March 2026.

RELMADA Therapeutics Director Fabiana Fedeli acquired 164,000 Stock Appreciation Rights with an exercise price of $4.06, vesting quarterly starting March 2026.

RELMADA Therapeutics Director John Glasspool was granted 164,000 Stock Appreciation Rights with an exercise price of $4.06, vesting quarterly starting March 2026.

RELMADA THERAPEUTICS, INC. COO and Director Paul Edward Kelly was granted 828,000 stock appreciation rights with an exercise price of $4.06, vesting quarterly starting March 2026.

RELMADA Therapeutics Director Charles J. Casamento was granted 164,000 Stock Appreciation Rights with an exercise price of $4.06, vesting quarterly starting March 12, 2026.

RELMADA Therapeutics' Chief Financial Officer, Maged Shenouda, purchased 500,000 shares of common stock at $2.20 per share, increasing his direct beneficial ownership.

RELMADA Therapeutics' Chief Administrative and Operating Officer, Chuck Ence, purchased 136,000 shares of common stock at $2.20 per share.

Relmada Therapeutics CEO Sergio Traversa acquired 272,500 shares of common stock at $2.20 per share, increasing his direct beneficial ownership.

RELMADA Therapeutics' Chief Operating Officer, Paul Edward Kelly, acquired 90,000 shares of common stock at $2.20 per share.

Relmada Therapeutics CEO Sergio Traversa acquired 265,976 shares of common stock in open market transactions over three days in late August 2025.

RELMADA Therapeutics, Inc. has granted 400,000 stock options to its Chief Accounting Officer and Chief Operating Officer, Chuck Ence, with an exercise price of $0.67, vesting quarterly over four years.

RELMADA Therapeutics' Chief Financial Officer, Maged Shenouda, was granted 600,000 stock options with an exercise price of $0.67, vesting quarterly starting September 26, 2025.

RELMADA Therapeutics, Inc. CEO Sergio Traversa has reported the acquisition of 800,000 stock options with an exercise price of $0.67, vesting quarterly over ten years.

RELMADA Therapeutics, Inc. Director Charles J. Casamento was granted 100,000 stock options with an exercise price of $0.67, vesting quarterly starting September 26, 2025.

Relmada Therapeutics Director John Glasspool was granted 100,000 stock options with an exercise price of $0.67, vesting quarterly starting September 26, 2025.

Director Fabiana Fedeli acquired stock options in Relmada Therapeutics, Inc. on June 26, 2025.

Paul Edward Kelly, Chief Operating Officer and Director of RELMADA Therapeutics, Inc., was granted 400,000 stock options with an exercise price of $0.67, vesting quarterly starting September 26, 2025.

Relmada Therapeutics' Chief Operating Officer, Paul Edward Kelly, recently acquired 200,000 shares of common stock in the open market at an average price of $0.4303 per share.

Maged Shenouda, CFO of Relmada Therapeutics, recently acquired a significant number of common stock shares through open market purchases.

Chuck Ence, an officer at Relmada Therapeutics, recently purchased 228,961 shares of common stock at a weighted average price of $0.4513 per share.

Relmada Therapeutics CEO Sergio Traversa has been actively purchasing company stock on the open market, significantly increasing his holdings.

Director Charles J. Casamento reports a disposition of 13,000 common stock shares of Relmada Therapeutics, Inc. through a gift.

Relmada Therapeutics CEO Sergio Traversa has been actively purchasing company stock on the open market, signaling confidence in the firm's prospects.

Director Charles J. Casamento of Relmada Therapeutics, Inc. purchased 13,000 shares of common stock at $2.56 per share on September 9, 2024.

Maged Shenouda, CFO of Relmada Therapeutics, recently acquired a significant number of common stock shares through open market purchases.

Director Paul Kelly of Relmada Therapeutics increased his holdings by purchasing 25,000 shares of common stock at an average price of $2.59 on September 9, 2024.

Relmada Therapeutics CEO Sergio Traversa received options for 122,358 shares and immediately forfeited them to the company for reallocation to other employees.

Maged Shenouda, CFO of Relmada Therapeutics, reports acquiring and forfeiting stock options related to the company's 2021 Equity Incentive Plan.